Heparin-induced effects of prothrombin complex concentrates in thromboelastometry

Wiener Klinische Wochenschrift

Volumn 124, Issue 9-10, 2012, Pages 320-325

  Scharbert, Gisela ^a   Thaler, Ulrich ^a   Weilnböck, Christoph ^a   Wetzel, Léonore ^a   Kozek Langenecker, Sibylle ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Evangelical Hospital Vienna   (Austria)

Author keywords

Heparin; Prothrombin complex concentrate; Rotational thromboelastometry

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; COFACT; HEPARIN; PROTAMINE; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; BLOOD CLOTTING; CONCENTRATION RESPONSE; ETHICS; FEMALE; FUNCTION TEST; HUMAN; IN VITRO STUDY; INFORMED CONSENT; MALE; NORMAL HUMAN; THROMBOELASTOMETRY; THROMBOGENESIS;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPARIN; HUMANS; THROMBELASTOGRAPHY;

EID: 84863717476     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-012-0171-8     Document Type: Article

References (28)

1. Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95:3-6.
2. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967-70.
3. Takeyama M, Sakurai Y, Shima M, Matsumoto T, Nogami K, Tanaka I, et al. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. Blood Coagul Fibrinolysis. 2007;18:1-7. (Pubitemid 46006266)
4. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-31. (Pubitemid 351404929)
5. Lavenne-Pardonge E, Itegwa MA, Kalaai M, Klinkenberg G, Loncke JL, Pelgrims K, et al. Emergency reversal of oral anticoagulation through PPSB-SD: the fastest procedure in Belgium. Acta Anaesthesiol Belg. 2006;57:121-5. (Pubitemid 44060663)
6. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401-15. (Pubitemid 47249577)
7. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;62:1614-22.
8. Nielsen VG. The detection of changes in heparin activity in the rabbit: a comparison of anti-Xa activity, thromboelastography, activated partial thromboplastin time, and activated coagulation time. Anesth analg. 2002;95(6):1503-6. (Pubitemid 35423932)
9. Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth analg. 2000;91(5):1091-5.
10. Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J clin pathol. 2000;113(5):725-31. (Pubitemid 33044314)
11. Pfanner G, Koscielny J, Pernerstorfer T, Gutl M, Perger P, Fries D, et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist. 2007;56:604-11. (Pubitemid 46985728)
12. Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.
13. Schochl H, Solomon C, Schulz A, Voelckel W, Hanke A, Van Griensven M, et al. Thromboelastometry (Tem) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17(3-4):266-72.
14. Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg. 2000;90:1086-8. (Pubitemid 30253454)
15. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27:81-90. (Pubitemid 40515992)
16. Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis. 2005;16:301-10. (Pubitemid 40705054)
17. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313-20. (Pubitemid 44173049)
18. Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B, et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med. 1999;25:1105-10. (Pubitemid 29525066)
19. Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542-5.
20. Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465-70. (Pubitemid 44305727)
21. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:340-80.
22. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313-8. (Pubitemid 352016310)
23. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008;112:2242-7.
24. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7:557-8. (Pubitemid 351927721)
25. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56. (Pubitemid 47393577)
26. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med. 2010;68:68-76.
27. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576-83. (Pubitemid 40712703)
28. Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D, et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth. 2005;95:310-6. (Pubitemid 41487340)